Biomarker Testing
in Lung Cancer 

             

Why do I test?

Biomarker testing is used to drive treatment decisions in an approach known as personalised medicine, to ensure each patient receives the most appropriate treatment for their tumour. It has been shown that patients with biomarker results available at the time of their initial oncology consultation benefit from shorter times to treatment administration, compared with patients whose results are unavailable.1

Which biomarkers do I assess?

Tumours are identified by pathology and specific biological alterations known as biomarkers; targeted therapies are now available based on the results of biomarker testing.

Biomarkers identified as predictors of therapeutic efficacy in lung cancer include epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) gene fusions, ROS proto-oncogene 1 (ROS1) gene rearrangements, B-Raf proto-oncogene (BRAF) mutations and programmed cell death ligand-1 (PD-L1) expression.2-4

ALK, anaplastic lymphoma kinase; BRAF, B-Raf proto-oncogene; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PD-L1, programmed cell death ligand-1; ROS1, ROS proto-oncogene 1


Assessment of other emerging biomarkers, including human epidermal growth factor receptor 2 (HER2) mutations, Kristen rat sarcoma viral oncogene homolog (KRAS) mutations and MET amplifications, are also often considered when using extended genetic panels or when routine EGFR/ALK/ROS1/BRAF testing is negative.4, 5

The estimated biomarker prevalence ranges for patients with non-small cell lung cancer (NSCLC) are listed in the table below:

ALK, anaplastic lymphoma kinase; BRAF, B-Raf proto-oncogene; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PD-L1, programmed cell death ligand-1; ROS1, ROS proto-oncogene 1

EGFR mutation

EGFR mutations associated with NSCLC commonly occur between exons 18 and 21 of the EGFR gene. The two most prevalent EGFR mutations are an in-frame deletion of exon 19 (50% of patients’ samples) and L858R point mutation in exon 21 (40% of patients’ samples). Lung cancer tumours harbouring these sensitising mutations are sensitive to EGFR tyrosine kinase inhibitor (TKI) treatment.15

ALK fusions

ALK fusions occur when part of the ALK gene translocates to a partner gene, leading to the creation of a fusion oncogene. The most common partner gene implicated in NSCLC is EML4. Oncogenic EML4-ALK induces tumour formation in mice, which can be reduced after the administration of ALK-TKIs in vitro and in vivo.7

ROS1 rearrangements

ROS1 is a receptor tyrosine kinase of the insulin receptor family. Chromosomal rearrangements involving the ROS1 gene can lead to consecutive kinase activity and these mutations are associated with sensitivity to TKIs in vitro.8

BRAF mutations

BRAF is a protein kinase involved in the mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway, which is involved in cell growth, proliferation, survival and differentiation. Approximately 50% of BRAF mutations in NSCLC are due to a point mutation in exon 15 (V600E), with 50% due to non-V600E mutations.12 The V600E mutation results in oncogenic properties including enhanced ERK activity.12

PD-L1 expression

The programmed cell death-1 (PD-1)/PD-L1 pathway is an important checkpoint used by tumour cells to inhibit antitumour immune responses.16 In vitro assessment suggests that PD-L1 can be overexpressed by lung cancer cells through the actions of surrounding cytokines, which prevents T cell-mediated tumour cell elimination.16-18 PD-1/PD-L1 inhibitors are effective therapies in tumours with high PD-L1 expression since the interaction between immune cell PD-1 and tumour cell PD-L1 is prevented, thus promoting a natural immune response against the tumour.16

Mechanism of action of anti-PD-L1 therapy

PD-L1 expression leads to
immune cell evasion

Anti-PD-1/PD-L1 reverses
immune suppression

Figure adapted from Peters, et al. 201919
PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1

How PD-L1 testing can be useful for patients with NSCLC

Dr Federico Cappuzzo (Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy) discusses how PD-L1 testing can be useful for patients with NSCLC.

Visit iD PD-L1 for more information on PD-L1 testing.

Back to top

 

When do I test?

It is recommended that biomarker testing in advanced/metastatic NSCLC should occur at the initial disease diagnosis and during disease progression.2, 4

At diagnosis of advanced/metastatic NSCLC, it is recommended that all sample types (resected tumours, small biopsies and cytology samples) undergo pathological analysis to confirm the presence of tumour biomarkers, in order to determine the most appropriate treatment.2 Circulating tumour DNA (ctDNA) from blood (plasma) may be considered if a tumour sample cannot be obtained.4

In some cases, such as patients with EGFR mutations, a tumour rebiopsy at disease progression is recommended in order to guide future treatment decisions.2

Two stages of disease management that use biomarker testing to inform treatment decision

 

Results of such biomarker tests inform treatment decisions, therefore notifying the patient of results should be done in a timely manner. For example, it is suggested that the turnaround time to get available results from a requested mutational test should be less than ten working days.25

Back to top

 

 

How to obtain tissue required for testing

 

Types of specimen

Quality tumour tissue acquisition is vitally important in the clinical management of NSCLC, allowing biomarker testing and disease staging to be performed. Adequate tumour tissue acquisition at first biopsy allows multiple tests to be performed without resampling at a later date.

The three commonly used specimen types for biomarker testing are:

  • Tumour tissue biopsy
  • Cytology
  • Plasma ctDNA

Overview of different specimens used for biomarker testing in NSCLC2, 4, 26-29

Biomarker status can be determined using various sample types

ctDNA, circulating tumour DNA; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer

Determining the type of specimen to obtain depends on various factors such as the health of the patient and the biomarker test required. Some key considerations of tumour tissue and ctDNA specimens are presented in the figure below.

Overview of different specimens used for biomarker testing in NSCLC2,26,30,31

ctDNA, circulating tumour DNA

Techniques for acquiring specimens for biomarker testing

Tumour or cytology biopsies can be acquired through surgical and non-surgical techniques.

Surgical techniques

  • Video-assisted thoracoscopic surgery (VATS): A minimally invasive surgical procedure in which a thoracoscope is inserted into the chest via small incisions32
  • Mediastinoscopy: A surgical procedure used to examine the mediastinum by the insertion of a mediastinoscope33

Non-surgical techniques

  • Bronchial brushing via bronchoscopy: A small brush inserted via the mouth or nose that allows the removal of tumour cells from the lungs34
  • Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA): An endoscope with an ultrasound probe and biopsy needle that is inserted into the oesophagus and allows guided biopsy35
  • Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): A transbronchial approach involving FNA of mediastinal lesions using an endobronchial ultrasound probe36

EBUS guide for interventional bronchoscopists

The instructional animation below provides expert guidance on safely and optimally performing EBUS-TBNA.

ctDNA, part of the circulating cell-free DNA coming from tumour cells, can be extracted from plasma samples for molecular testing.37

Please refer to the Technical Considerations page to learn more about the methodologies and techniques used to test for biomarkers in NSCLC.

Back to top

 

Biomarker testing and treatment guidelines

NSCLC biomarker testing and treatment guidelines, including those from the American Society of Clinical Oncology (ASCO), College of American Pathologists (CAP)-International Association for the Study of Lung Cancer (IASLC)-Association for Molecular Pathology (AMP), Chinese Society of Oncology (CSCO)-European Society for Medical Oncology (ESMO), ESMO, National Comprehensive Cancer Network (NCCN) and Spanish Society of Medical Oncology (SEOM)-Spanish Society of Pathology (SEAP) suggest that all patients with advanced/metastatic NSCLC should be tested for biomarkers.2, 4, 5, 25, 38, 39 The PD-L1 immunohistochemistry test is now mandatory for all patients diagnosed with advanced NSCLC.2

Treatment recommendations for a patient with advanced NSCLC reflect the benefit of targeting the genetic abnormality driving the disease, where any is detected.2, 4 It has been shown that some tumours harbouring genetic mutations also express PD-L1 and treatment with PD-1/PD-L1 inhibitors in these patients is associated with low response rates.40 Therefore, it is recommended that targeted therapy against the genetic abnormality should take precedence over treatment with PD-1/PD-L1 therapies.4 Establishing the status of all relevant lung biomarkers before initiating treatment is essential.

The importance of obtaining all biomarker test results before starting treatment for NSCLC

In the interview below, Dr Federico Cappuzzo (Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy) discusses the importance of obtaining all biomarker test results before starting treatment for NSCLC.

Please refer to your local guidelines for guidance on treatment and management options in NSCLC.

Back to top

  1. Lim C, Tsao MS, Le LW, et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol 2015;26:1415–1421
  2. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv192–iv237
  3. Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book 2019;39:531–542
  4. NCCN. Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer Version 3.2020. 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed: 11 June 2020
  5. Garrido P, Conde E, de Castro J, et al. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2019;[Online ahead of print]
  6. Zhang Y-L, Yuan J-Q, Wang K-F, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7:78985–78993
  7. Du X, Shao Y, Qin H-F, et al. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer 2018;9:423–430
  8. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863–870
  9. Lin Q, Zhang H, Ding H, et al. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. J Transl Med 2019;17:298–298
  10. Brustugun OT, Khattak AM, Tromborg AK, et al. BRAF-mutations in non-small cell lung cancer. Lung Cancer 2014;84:36–38
  11. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013;19:4532–4540
  12. Leonetti A, Facchinetti F, Rossi G, et al. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev 2018;66:82–94
  13. Dietel M, Savelov N, Salanova R, et al. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter EXPRESS study. Lung Cancer 2019;134:174–179
  14. Aggarwal C, Abreu DR, Felip E, et al. Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024. Ann Oncol 2016;27(supplement 6):vi359–vi378
  15. Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol 2018;29:i3–i9
  16. Kim H, Chung JH. PD-L1 testing in non-small cell lung cancer: past, present, and future. J Pathol Transl Med 2019;53:199–206
  17. Chen S, Crabill GA, Pritchard TS, et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer 2019;7:305
  18. Lastwika KJ, Wilson W, 3rd, Li QK, et al. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res 2016;76:227-238
  19. Peters S, Cho BC, Reinmuth N, et al. Abstract CT074: tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): blood and tissue TMB analysis from MYSTIC, a phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.  AACR Annual Meeting 2019; Atlanta, GA, USA 2019. CT074–CT074
  20. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327–3334
  21. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–2388
  22. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–128
  1. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213–222
  2. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–1833
  3. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 2018;142:321–346
  4. Zito Marino F, Bianco R, Accardo M, et al. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. Int J Med Sci 2019;16:981–989
  5. Cheung CC, Barnes P, Bigras G, et al. Fit-for-purpose PD-L1 biomarker testing for patient selection in immuno-oncology: guidelines for clinical laboratories from the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Appl Immunohistochem Mol Morphol 2019;27:699–714
  6. Lozano MD, Echeveste JI, Abengozar M, et al. Cytology smears in the era of molecular biomarkers in non-small cell lung cancer: doing more with less. Arch Pathol Lab Med 2018;142:291–298
  7. Jenkins S, Yang JC, Ramalingam SS, et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer. J Thorac Oncol 2017;12:1061–1070
  8. Schwaederle M, Husain H, Fanta PT, et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget 2016;7:9707–9717
  9. Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J 2018;16:370–378
  10. MayoClinic. Video-assisted thoracoscopic surgery (VATS). 2020. Available from: https://www.mayoclinic.org/tests-procedures/video-assisted-thoracic-surgery/about/pac-20384922. Accessed: 11 June 2020
  11. Patient.Info. Mediastinoscopy. 2019. Available from: https://patient.info/treatment-medication/mediastinoscopy. Accessed: 11 June 2020
  12. Cancer.gov. Bronchial brushing. 2020. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bronchial-brushing. Accessed: 11 June 2020
  13. Cancer.gov. EUS-FNA. 2020. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/eus-fna. Accessed: 11 June 2020
  14. Patient.Info. Endobronchial ultrasound-guided transbronchial needle aspiration. 2016. Available from: https://patient.info/treatment-medication/endobronchial-ultrasound-guided-transbronchial-needle-aspiration. Accessed: 11 June 2020
  15. Goto T, Hirotsu Y, Amemiya K, et al. Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood. Oncotarget 2017;8:59268-59281
  16. Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017;35:3484–3515
  17. Wu YL, Planchard D, Lu S, et al. Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol 2019;30:171–210
  18. Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 2016;22:4585–4593